Federal Register Notice: FDA withdraws approval of an NDA for Tigan (trimethobenzamide hydrochloride) suppositories due to lack of substantial evidence of effectiveness. The agency declares that the marketing of unapproved trimethobenzamide hydrochloride suppository products is unlawful and subject to FDA regulatory action. To view this notice, click here.
